Yisheng Pharmaceutical: Received a risk control measure notice from the National Medical Products Administration, and the involved products, Shengmai injection and Bujin tablets, are suspended from production and sales.

Yisheng Pharmaceutical announced that the company received a notice from the Jilin Provincial Drug Administration, stating that due to serious defects in the product Bujin Tablets, the production lines for Shengmai Injection and Bujin Tablets have been suspended from production and sales. In 2025, the revenue from the involved products Shengmai Injection and Bujin Tablets accounted for 7.65% and 0.01% of the company's total revenue, respectively. The company has initiated a Class III recall of Bujin Tablets, and has not received any reports of adverse safety events so far. It will actively rectify the situation.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned